Failure to grow remains one of the commonest reasons for a child to be referred to a paediatric endocrinologist. Once referred, the clinical skill of the physician is key. This proposed continuing medical education programme places human clinical skill at the forefront of a learning journey highlighting digital solutions and innovations in growth disorders. Technological advances, Artificial Intelligence (AI), pharmacogenomics and virtual reality all play a supporting role within the assessment, diagnosis, management and treatment of patients requiring growth hormone treatment, but do not replace the doctor-patient relationship. AI alone will not make patients feel better or have the confidence to face a long-term illness. For this, the human touch is needed, with eye contact and encouraging words and the sensitivity to perceive changes in morale and mood, which are common during the course of any significant illness [Savage, 2025]. Although clinical skill is essential, technology can offer help and support, some of which will free clinician time to spend with patients. Working with technology is increasing in the field of growth disorders, from the use of software within medication dispensing devices to alert healthcare team members about patient adherence, to the use of facial recognition software to identify girls with Turner syndrome, or the use of neural networks to pinpoint those experiencing poor growth by digitally analysing hand radiographs [Ren, 2019] Pharmacogenomics is an exciting area destined to increase efficacy and safety of medications. The elements of this learning journey aim to update physicians on the latest developments in growth hormone management, while maintaining a grounded, physician-centric perspective. Many factors underpin decisions to implement new technology, and there is no doubt that innovation is driving personalisation of medicine and greater patient engagement.